Risk factors for disease progression in idiopathic pulmonary fibrosis Academic Article uri icon

Overview

MeSH Major

  • Lung
  • Pulmonary Disease, Chronic Obstructive
  • Smoking

abstract

  • In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality, respiratory and all-cause hospitalisations, and categorical disease progression. Predictive modelling of progression-free survival event risk was used to assess the effect of population enrichment for patients at risk of rapid progression of IPF; C-index values were 0.64 (death), 0.69 (disease progression), and 0.72 (adjudicated respiratory hospitalisation) and 0.76 (all-cause hospitalisation). Predictive modelling may be a useful tool for improving efficiency of clinical trials with categorical end points.

publication date

  • January 2020

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1136/thoraxjnl-2019-213620

PubMed ID

  • 31611341

Additional Document Info

start page

  • 78

end page

  • 80

volume

  • 75

number

  • 1